Global CRO PPD announced it is expanding its operations and leadership in China to offer enhanced clinical development, laboratory, regulatory, site conduct, patient access, and post-approval services for international and China-based biopharmaceutical companies. The CRO seeks to capitalize on the rapid growth of the drug development business in the world’s most populous country.
Clinical Development Offices
PPD will expand its clinical development offices in Beijing and Shanghai while opening up new offices in Guangzhou and Shenyang. In 2020, PPD Laboratories seeks to open a multifunctional lab in China offering bioanalytical, biomarker, and vaccine sciences services. Additionally, the company’s Accelerated Enrollment Solutions (AES) business—offering distinctive site conduct and patient access solutions—added China to its global footprint for delivery of performance-based enrollment solutions for chronic ambulatory trials, leveraging its partnership with more than 300 hospitals in China.
Growing Experience in China
PPD’s growing operations in China are being led by new in-country leadership with extensive experience across the pharmaceutical and biotech industry and ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).